56 min
Biotech trends you need to know Molecule to Market: Inside the outsourcing space
-
- Life Sciences
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Allan Shaw, Consulting CFO, Special Advisor & Board Member of several biotech companies. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Allan, covering:
The sensitive cash position of biotech's as a ‘hangover’ after a decade of partying as the market was high.
The potential domino effect and collateral impact of the biotech capital slowdown on the supply chain ecosystem.
Core commonalities between biotech's of all shapes and sizes, and what challenges they face today.
How CRO/CDMO and other pharma services’ vendors can add the most value during an expected bumpy ride for biotech's.
Allan is a senior biopharmaceutical executive and board member with 20+ years of international and transactional experience. He is a five-time public company CFO and has served on six public boards, which included the chairing of two audit and two compensation committees. He is currently involved with a portfolio of healthcare activities, including serving as Portage Biotech’s Chief Financial Officer. Prior, Shaw also served as managing director and life science practice leader for Alvarez & Marsal’s healthcare industry group. He was also CFO at Serono.
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Allan Shaw, Consulting CFO, Special Advisor & Board Member of several biotech companies. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Allan, covering:
The sensitive cash position of biotech's as a ‘hangover’ after a decade of partying as the market was high.
The potential domino effect and collateral impact of the biotech capital slowdown on the supply chain ecosystem.
Core commonalities between biotech's of all shapes and sizes, and what challenges they face today.
How CRO/CDMO and other pharma services’ vendors can add the most value during an expected bumpy ride for biotech's.
Allan is a senior biopharmaceutical executive and board member with 20+ years of international and transactional experience. He is a five-time public company CFO and has served on six public boards, which included the chairing of two audit and two compensation committees. He is currently involved with a portfolio of healthcare activities, including serving as Portage Biotech’s Chief Financial Officer. Prior, Shaw also served as managing director and life science practice leader for Alvarez & Marsal’s healthcare industry group. He was also CFO at Serono.
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.
56 min